Synapse - Yelena Janjigian

Search Within

Yelena Yuriy Janjigian

Results (400)

KEYNOTE-859: A phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma

Journal Article

Tabernero, J.; Bang, Y. J.; Van Cutsem, E.; Fuchs, C. S.; Janjigian, Y. Y.; Bhagia, P.; Li, K.; Adelberg, D.; Qin, S. K.
Future Oncology (2021)

Fulltext@MSK | Save

Initial data from the phase 3 KEYNOTE-811 study of trastuzumab and chemotherapy with or without pembrolizumab for HER2-positive metastatic gastric or gastroesophageal junction (G/GEJ) cancer

Meeting Abstract

Janjigian, Y.; Kawazoe, A.; Weber, P.; Luo, S.; Lonardi, S.; Kolesnik, O.; Barajas, O.; Bai, Y.; Shen, L.; Tang, Y.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Frequency of minimal residual disease as measured by ctDNA in mismatch repair deficient tumors following curative resection

Meeting Abstract

Janjigian, Y.; Lumish, M.; Jayakumaran, G.; Fox, M.; Sabwa, S.; Cercek, A.; Stadler, Z.; Ku, G.; Segal, N.; Won, E.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015

Meeting Abstract

Tabernero, J.; Cohen, D.; Van Cutsem, E.; Janjigian, Y.; Bang, Y.; Qin, S.; Wang, A.; Hawk, N.; Shih, C.; Bhagia, P.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress

Meeting Abstract

Strickler, J.; Nakamura, Y.; Shitara, K.; Catenacci, D.; Janjigian, Y.; Barzi, A.; Bekaii-Saab, T.; Lenz, H.; Lee, J.; Van Cutsem, E.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

MATTERHORN: A phase 3 study of efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer

Meeting Abstract

Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Al-Batran, S.; Hyung, W.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial

Journal Article

Janjigian, Y. Y.; Shitara, K.; Moehler, M.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Bragagnoli, A. C.; more...
Lancet (2021)

Fulltext@MSK | Save

Prevalence of germline alterations on targeted tumor-normal sequencing of esophagogastric cancer

Journal Article

Ku, G. Y.; Kemel, Y.; Maron, S. B.; Chou, J. F.; Ravichandran, V.; Shameer, Z.; Maio, A.; Won, E. S.; Kelsen, D. P.; Ilson, D. H.; more...
JAMA Network Open (2021)

Fulltext@MSK | Save

Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab ± ipilimumab in gastric cancer/gastroesophageal junction cancer

Journal Article

Lei, M.; Siemers, N. O.; Pandya, D.; Chang, H.; Sanchez, T.; Harbison, C.; Szabo, P. M.; Janjigian, Y.; Ott, P. A.; Sharma, P.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Comparison of long- and short-term outcomes in 845 open and minimally invasive gastrectomies for gastric cancer in the United States

Journal Article

Nakauchi, M.; Vos, E.; Janjigian, Y. Y.; Ku, G. Y.; Schattner, M. A.; Nishimura, M.; Gonen, M.; Coit, D. G.; Strong, V. E.
Annals of Surgical Oncology (2021)

Fulltext@MSK | Save